2013
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Iyengar N, Morris P, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 167-167. DOI: 10.1200/jco.2013.31.26_suppl.167.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCongestive heart failureDistant disease-free survivalEarly breast cancerBreast cancerHER2-positive early breast cancerMedian left ventricular ejection fractionLong-term cardiac safetyRandomized phase III studyEarly-stage breast cancerLong-term cardiac toxicityTrial BTrial AAnthracycline-based regimensDose-dense doxorubicinPre-existing hypertensionPhase II studyDisease-free survivalPhase III studyVentricular ejection fractionStage breast cancerDd ACMonths 44II studyIII studyLonger-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Morris P, Iyengar N, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 630-630. DOI: 10.1200/jco.2013.31.15_suppl.630.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCongestive heart failureDistant disease-free survivalEarly breast cancerBreast cancerHER2-positive early breast cancerMedian left ventricular ejection fractionLong-term cardiac safetyMedian f/uRandomized phase III studyEarly-stage breast cancerLong-term cardiac toxicityTrial BTrial AAnthracycline-based regimensCompletion of ACDose-dense doxorubicinPre-existing hypertensionDisease-free survivalPhase II studyPhase III studyVentricular ejection fractionStage breast cancerDd ACMonths 44
2011
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF. A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA 2011, 305: 1873-1881. PMID: 21558518, PMCID: PMC5638042, DOI: 10.1001/jama.2011.593.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlgorithmsAnthracyclinesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleBreast NeoplasmsBridged-Ring CompoundsDisease-Free SurvivalDrug Resistance, NeoplasmFemaleForecastingGene Expression ProfilingGenes, erbB-2Genes, NeoplasmGenomicsHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalOligonucleotide Array Sequence AnalysisPredictive Value of TestsPrognosisProspective StudiesReceptors, EstrogenRiskTaxoidsConceptsDistant relapse-free survivalInvasive breast cancerBreast cancerGenomic predictorsD. Anderson Cancer CenterAnthracycline-based regimensER-negative subsetExcellent pathologic responseProspective multicenter studyRelapse-free survivalAbsolute risk reductionStandard cancer treatmentPredictors of responseIndependent validation cohortAnderson Cancer CenterNegative breast cancerCancer treatment strategiesSequential taxaneNeoadjuvant chemotherapyPreoperative chemotherapyPathologic responseWorse survivalEndocrine sensitivityER statusMulticenter study
2010
Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers
Lehmann‐Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa L, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, Thé H. Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers. The Oncologist 2010, 15: 246-252. PMID: 20228131, PMCID: PMC3227956, DOI: 10.1634/theoncologist.2009-0243.Peer-Reviewed Original ResearchConceptsPathologic complete responseBreast cancer patientsCancer patientsDose intensificationDose intensityP53 statusAnthracycline resistanceHigh-dose cyclophosphamide administrationP53-mutant breast cancersAnthracycline-based regimensTriple-negative tumorsPretreatment tumor samplesMutant breast cancerChemotherapy regimensComplete responseER expressionCyclophosphamide administrationER- tumorsTumor responsePooled resultsBreast cancerYeast functional assayPatientsPredictive valueMultivariate analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply